About PER - Careers

Physicians' Education Resource (PER) is medical publishing and education company specializing in Oncology. As a subsidiary of MMH Partners L.P., we are associated with several other subsidiaries dedicated to providing improved treatment and care to cancer patients through educational programs.

Company Background

PER is dedicated to coordinating and implementing superior educational opportunities that enable physicians and health care professionals to remain current and responsive to advances in medical care. PER's ultimate goal is to accelerate the transfer of the rapidly evolving findings in oncology to the practicing physician in order to sustain high quality, cost-effective patient care. PER may present locally, regionally, nationally or internationally as deemed appropriate. We provide a variety of instructional formats, including CME accredited conferences, protocol meetings, and educational publications, audio, video and other enduring materials.

PER was founded in 1996 and has expanded significantly in products and services ever since. We currently have over 135 employees and have experienced continual growth since our inception. We are located in the Uptown area of Dallas, TX.

Company Benefits

We offer a competitive compensation and benefits package consisting of the following:

Medical - choice of 2 insurance plans

Dental Insurance

Vision Insurance

100% subsidized Short & Long Term Disability

100% subsidized Life Insurance

Free enrollment in company Wellness Program

Onsite fitness center

Free parking

Access to Katy Trail and Turtle Creek Trails

Questions about PER Careers?

For more infomation about careers and benefits at Physicians' Education Resource, please email Jennifer Cunnings at jennifer.cunnings@mmhlp.com.

Online CME Updates

NSCLC TODAY

Treatment of a 62-Year-Old Patient With Metastatic NSCLC After a Platinum Doublet

Get updates on the latest developments in maintenance therapy for patients with advanced non–small-cell lung cancer.

Go to activity >>

ADJUVANT THERAPY

Treatment of a 53-Year-Old Man With Stage IIA NSCLC

Learn about recent clinical data on adjuvant therapy in patients with resected early-stage non–small-cell lung cancer and the role of biomarkers in predicting benefit from adjuvant therapy. 

Get started >>

TREATMENT OPTIONS

E-Lert: Updates in Advanced Melanoma From the 46th Annual Meeting of ASCO

Advanced melanoma is a difficult-to-treat malignancy. Listen and find out about novel therapies in recent clinical trials to treat patients with advanced melanoma.

Learn more >>